Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Biotech Consultancy Services: Myths and Realities

Jun 27, 2025

Understanding Biotech Consultancy Services

Biotech consultancy services are often misunderstood and shrouded in mystery. These services are crucial for guiding biotechnology companies through complex regulatory landscapes and scientific challenges. Yet, myths surrounding their function and effectiveness persist. This article aims to clear up these misconceptions and highlight the realities of biotech consultancy services.

biotech lab

Myth: Biotech Consultants Are Unnecessary

One prevalent myth is that biotech consultants are an unnecessary expense. Some believe that in-house teams can handle all aspects of biotechnology projects. However, the reality is that consultants bring specialized expertise that might not be available internally. They provide strategic insights, regulatory guidance, and market analysis that can be invaluable for navigating the competitive biotech industry.

Consultants can help businesses avoid costly mistakes by ensuring compliance with regulations and assisting with product development strategies. Their external perspective can also offer fresh ideas and innovative solutions, which can significantly enhance a company’s growth potential.

Reality: Diverse Expertise and Experience

Biotech consultants come with a wealth of experience from various segments of the industry. They have often worked across multiple projects and companies, giving them a broad understanding of common pitfalls and successful strategies. This diverse expertise is crucial for companies aiming to innovate and scale.

scientists meeting

Furthermore, biotech consultants are adept at identifying trends and opportunities in the market. Their ability to provide data-driven analysis and actionable insights makes them an essential partner for biotech companies looking to stay ahead of the curve.

Myth: Consulting Is Only for Large Companies

Another common myth is that consulting services are only beneficial for large or established companies. The truth is that startups and small businesses can benefit tremendously from consultancy services. In fact, early-stage companies may have more to gain from expert guidance as they navigate the initial challenges of the biotech landscape.

Consultants can assist these smaller entities in securing funding, managing resources efficiently, and developing a strategic business plan. By leveraging a consultant’s expertise, even a small startup can compete with larger players in the industry.

small business meeting

Reality: Tailored Solutions

Biotech consultancy services are not a one-size-fits-all solution. Consultants work closely with clients to develop tailored strategies that align with specific business goals and challenges. Whether it's navigating regulatory approvals or optimizing R&D efforts, consultants offer customized approaches that address the unique needs of each client.

This personalized attention ensures that companies receive the support they need to overcome obstacles and capitalize on opportunities in their specific niche within the biotechnology sector.

The Future of Biotech Consultancy

As the biotech industry continues to evolve, the role of consultants will become increasingly important. With advancements in technology and growing regulatory complexities, having expert guidance will be crucial for success. Companies that embrace consultancy services are likely to be better equipped to innovate and thrive in this dynamic field.

In conclusion, while myths about biotech consultancy services abound, the reality is that these professionals offer valuable expertise and support to companies of all sizes. By debunking these myths, businesses can better appreciate the strategic advantage that consultants provide in helping them achieve their objectives.